Format

Send to

Choose Destination
Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315.

Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.

Author information

1
Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece markos523@yahoo.gr.
2
Immuno-Oncologic Center Köln, Köln, Germany.
3
Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece.
4
Department of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg an der Saar, Germany.

Abstract

BACKGROUND/AIM:

The need for more effective treatment modalities that can improve the clinical outcome of patients with glioblastoma multiforme remains imperative. Dendritic cell vaccination is a fast-developing treatment modality, currently under exploration. Functional immune cell subpopulations may play a role in the final outcome.

MATERIALS AND METHODS:

Data from 101 patients drawn from the HGG-2010 trial, including baseline patient characteristics and fluorescence-activated cell sorting of immune cell subpopulations, were analyzed by statistical and machine-learning methods.

RESULTS:

The analysis revealed strong correlations between immune profiles and overall survival, when the extent of resection and the vaccination schedule were used as stratification variables.

CONCLUSION:

A systematic, in silico workflow detecting strong and statistically significant correlations between overall survival and immune profile-derived quantities obtained at the start of dendritic cell vaccination was devised. The derived correlations could serve as a basis for the identification of prognostic markers discriminating between potential long- and short-term survivors of patients with glioblastoma multiforme.

KEYWORDS:

GBM; biomarker; circulating lymphocytic phenotype; dendritic cell vaccination; glioblastoma multiforme; immunotherapy; malignant glioma; overall survival

PMID:
30952748
DOI:
10.21873/anticanres.13315
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center